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The class III histone deactylase (HDAC), SIRT1, has cancer relevance because it regulates lifespan in multiple organisms,
down-regulates p53 function through deacetylation, and is linked to polycomb gene silencing in Drosophila. However,
it has not been reported to mediate heterochromatin formation or heritable silencing for endogenous mammalian
genes. Herein, we show that SIRT1 localizes to promoters of several aberrantly silenced tumor suppressor genes (TSGs)
in which 59 CpG islands are densely hypermethylated, but not to these same promoters in cell lines in which the
promoters are not hypermethylated and the genes are expressed. Heretofore, only type I and II HDACs, through
deactylation of lysines 9 and 14 of histone H3 (H3-K9 and H3-K14, respectively), had been tied to the above TSG
silencing. However, inhibition of these enzymes alone fails to re-activate the genes unless DNA methylation is first
inhibited. In contrast, inhibition of SIRT1 by pharmacologic, dominant negative, and siRNA (small interfering RNA)–
mediated inhibition in breast and colon cancer cells causes increased H4-K16 and H3-K9 acetylation at endogenous
promoters and gene re-expression despite full retention of promoter DNA hypermethylation. Furthermore, SIRT1
inhibition affects key phenotypic aspects of cancer cells. We thus have identified a new component of epigenetic TSG
silencing that may potentially link some epigenetic changes associated with aging with those found in cancer, and
provide new directions for therapeutically targeting these important genes for re-expression.
Citation: Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SHL, et al. (2006) Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA
hypermethylation. PLoS Genet 2(3): e40.
Introduction
A growing list of tumor suppressor genes (TSGs) and
candidate TSGs are epigenetically silenced in virtually every
cancer type, and this silencing has been associated with
aberrant promoter DNA methylation [1–3]. In previous
studies, silencing of these genes was shown to involve dense
hypermethylation of 59 CpG islands and hypoacetylation of
lysine 9 and 14 on histone H3 (H3-K9 and H3-K14,
respectively) [4,5]. Moreover, synergistic reactivation of these
TSGs can be achieved only when class I/II histone deactylase
(HDAC) inhibitors (HDIs) are employed to treat tumor cells
after DNA demethylating agents, such as 5-deoxy-azacytidine
(DAC), have ﬁrst induced at least partial promoter demethy-
lation [5,6]. This suggested a dominance of the DNA
methylation over H3-K9/K14 deactylation for maintenance
of the gene silencing [1]
Another important class of HDACs, the NAD
þ-dependent
sirtuins, or class III HDACs [7], has recently received much
attention. The most prominent human family member, SIRT1
(Q96EB6), has only been shown to regulate transcriptional
repression of mammalian target genes that are either already
basally expressed [8] or to regulate transcriptional repression
of an integrated Gal4-fusion reporter plasmid [9–11]. Thus
far, SIRT1 has not been linked to heterochromatin main-
tenance or heritable silencing of TSGs, nor has it been well
studied for endogenous mammalian genes. The sirtuins have
distinct speciﬁc inhibitors [12–14] and are not responsive to
drugs like trichostatin-A (TSA) or other class I and II HDIs
previously used to study promoter-hypermethylated TSGs. At
least eight different class I/II HDIs are advancing in different
phases of clinical trials for cancer treatment [15,16], but
inhibitors of sirtuin deacetylases have not been investigated
for such use. The human class III HDAC, SIRT1, already has
cancer relevance because it regulates gene silencing and/or
lifespan in multiple organisms [17–20], regulates p53 function
[21–23], and plays a critical role in stress signaling [24,25]. In
addition, the yeast SIRT1 ortholog, Sir2, directly mediates
histone-dependent gene silencing [7,26], and its counterpart
in Drosophila has been linked to polycomb gene silencing [27].
However, SIRT1 has not been demonstrated to mediate
heritable silencing for endogenous mammalian genes.
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To determine whether SIRT1 speciﬁcally plays a role in
silencing TSGs whose promoters have 59 CpG islands that are
densely hypermethylated, we ﬁrst applied screens using RNA-
interference (RNAi) to disrupt the function of this protein
and evaluate the effects on the targets. Both breast and colon
cancer cell lines were chosen for our study, and several RNAi
sequences targeting SIRT1 speciﬁcally were tested for their
efﬁcacy. SIRT1 protein levels in both MCF7 (Figure 1A) and
MDA-MB-231 (Figure 1B) breast cancer cells were reduced via
retroviral infection with a pSuper-retro-RNAi construct
encoding short hairpin loop RNA (shRNA) speciﬁc for
‘‘knocking down’’ SIRT1. Three RNAi constructs were tested,
and the sequence termed RNAi-3 yielded the greatest
knockdown in MCF7 (Figure 1A), whereas both RNAi-2 and
RNAi-3 were very effective in reducing protein levels in
MDA-MB-231 cells (Figure 1B). Since we infected cells with
equivalent titers of virus encoding the shRNAs, we are not
sure why RNAi-3 was the most effective, but as shown below,
the degree of knockdown served as a good control since it
correlates very well with effects on gene re-expression.
Strikingly, and correlating with the knockdown pattern of
SIRT1 in each cell type, we observed re-expression of key
TSGs that are frequently epigentically silenced in a number
of different cancers. The anti-tumor genes identiﬁed all have
promoter DNA hypermethylation, and they have important
anti-tumor functions ranging from mediating proper epi-
thelial cell differentiation to promoting cell–cell adhesion.
The genes include members of the family of secreted frizzled-
related proteins (SFRP1 and SFRP2), which are frequently
epigenetically inactivated during colon and breast cancer
progression, and contribute to aberrant activation of Wnt
signaling (Figure 1C and 1D) [6,28]. Additionally, SIRT1 was
found to maintain silencing of E-cadherin, a gene mediating
cell–cell adhesion that is also inactivated epigenetically in
many cancers (Figure 1D) [29–31]. Finally, SIRT1 protein
levels were also reduced in RKO colon cancer cells and
SIRT1was found to maintain silencing of TSGs including the
mismatch repair gene, MLH1 (Figure 1E), for which epige-
netic silencing and loss of function produces the micro-
satellite instability (MINþ) colon cancer phenotype [32,33] .
Additionally, we found that the transcription factors encod-
Figure 1. siRNA Knockdown of SIRT1 Causes Re-Expression of Epigeneti-
cally Silenced TSGs
(A) RNAi-3 is most effective for reduction of SIRT1 in MCF7 cells.
Retroviral expression vectors encoding SIRT1 cDNA that produce short
hairpin loop RNA targeting either distinct regions of SIRT1 mRNA (RNAi-
1,  2, or  3) or a control (ctrl) were used to infect MCF7. Western blot
analysis for SIRT1 and b-actin was performed 48 h after two rounds of
infection.
(B) Both RNAi-2 and  3 are effective for reduction of SIRT1 protein in
MDA-MB-231 cells as described in (A).
(C) SIRT1 inhibition leads to TSG re-expression in MCF7 cells. RNA was
isolated from parallel samples analyzed in (A), and RT-PCR was
performed with intron-spanning primers specific for the genes SFRP1
and SFRP2. GAPDH was also analyzed as a control. Only the shRNA (RNAi-
3) that caused substantial reduction in SIRT1 protein leads to gene re-
expression. Control samples in which no reverse transcriptase was added
were analyzed separately, and all were negative for amplification of the
indicated genes.
(D) SIRT1 inhibition leads to TSG re-expression in MDA-MB-231 cells. RT-
PCR was performed for analysis of the genes SFRP1, SFRP2, and E-
cadherin as described in (A). Only the shRNAs (RNAi-2 and  3) that
caused substantial reduction in SIRT1 protein lead to gene re-expression
(E) SIRT1 inhibition leads to TSG re-expression in RKO cells. SIRT1 protein
reduction by RNAi-3 (top panel) as described in (A) leads to gene re-
expression of SFRP1, SFRP2, and MLH1 as described in (C)
(F) MDA-MB-231 and RKO cells infected with control or RNAi-3 shRNA as
described in (A) were selected with puromycin for 3 d, and pooled
colonies were harvested for Western blot analysis of protein re-
expression that corresponded with the gene reactivation described in
(D) and (E).
DOI: 10.1371/journal.pgen.0020040.g001
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Synopsis
The propensity for cancer to arise and progress is influenced not
only by gene mutations (genetic abnormalities), but also by defects
in gene expression programs that are inherited from one dividing
cell to another. This change in the inheritance of gene expression
patterns not associated with changes in the primary DNA sequence
is referred to as an epigenetic abnormality. In virtually every form of
cancer, tumor suppressor genes (TSGs) and candidate TSGs are
epigenetically altered such that the ability of these genes to become
activated and lead to production of the corresponding proteins is
lost. This so-called gene ‘‘silencing’’ is often linked with abnormal
accumulation of methyl groups to DNA (DNA methylation) in a
region of the gene that controls its expression. The SIRT1 protein is
an enzyme that can remove acetyl groups attached to specific
amino acids in a number of different protein targets and thereby
regulate gene silencing in yeast. However, in mammalian cells this
has not been demonstrated. Here, the authors show SIRT1 is
involved in epigenetic silencing of DNA-hypermethylated TSGs in
cancer cells. Inhibition of SIRT1 by multiple approaches leads to TSG
re-expression and a block in tumor-causing networks of cell
signaling that are activated by loss of the TSGs in a wide range of
cancers. This finding has important ramifications for the biology of
cancer in terms of what maintains abnormal gene silencing.
Furthermore, the authors propose that their observations may have
potential clinical relevance in suggesting new means for restoring
expression of abnormally silenced genes in cancer.ing GATA-4 and GATA-5 genes, whose promoter DNA is
hypermethylated [34], were also re-expressed in both colon
and breast cancer cells (unpublished data).
To further determine whether the gene re-expression with
this very speciﬁc approach for SIRT1 inhibition leads to
protein re-expression, we performed parallel Western blots
on samples for which proven antibodies are available.
Consistent with gene re-expression, we found restoration of
E-cadherin protein in breast and colon cancer cell lines and
MLH1 in colon cancer lines in which these genes are
hypermethylated and silenced (Figure 1F). These ﬁndings
further demonstrate that SIRT1 speciﬁcally, and substantially,
contributes to the aberrant heritable silencing of our panel of
TSGs. Moreover, the levels of gene expression when SIRT1
function is reduced is similar to that observed for these genes
when moderate doses of 59-aza-deoxycytidine (Aza) is
employed to achieve promoter demethylation [32,35]. Fur-
thermore, we have demonstrated previously that the degree
of protein re-expression for MLH1 obtained correlates with
restored protein function in RKO cells [32].
To further assess the role SIRT1 plays in silencing TSGs
whose promoter DNA is hypermethylated, we used two
additional approaches. We applied a pharmacologic ap-
proach using the general sirtuin inhibitor, nicotinamide
(NIA) [12,36], and the more sir2-speciﬁc inhibitor, splitomicin
(SPT) [13,37]. Consistent with our above RNAi data, we found
that these sirtuin inhibitors could cause the re-expression of
the epigenetically silenced, hypermethylated TSGs studied
above, and another such gene, CRBP1, in the human breast
cancer cell lines MDA-MB-231 (Figure 2) or MCF7 (unpub-
lished data). Using yet a third approach to assess the role that
SIRT1 plays, we expressed a catalytically inactive, dominant
negative inhibitor of SIRT1, SIRT1H363Y [21], and screened
representative genes to further validate the speciﬁc involve-
ment of this protein in repression of our panel of hyper-
methylated TSGs. In both MCF7 and MDA-MB-231 breast
cancer cells in which SIRT1H363Y was expressed through
retroviral infection, we observed a re-expression of
SFRP1and SFRP2 (Figure 2E and 2F [left panel]). Additionally,
we saw the same effect for GATA-4 in HCT116 colon cancer
cells when the H363Y mutant was expressed, but not the wild
type (unpublished data).
As discussed earlier, we have demonstrated previously that
DNA methylation and histone deacetylation, involving class I
and II HDACs, act as synergistic layers for TSG silencing in
cancer and that inhibition of DNA methylation is dominant
relative to the inhibition of deacetylation [6]. Thus, we also
wanted to determine whether disruption of sirtuin function
could collaborate with either inhibitors of DNA methylation
or class I/II HDIs in TSG re-expression. In this regard, low
doses of Aza (50 nM) or SPT (50 lM) that were ineffective as
single agents could be combined to achieve synergistic re-
expression of our gene panel as shown by representative
genes in Figure 2B.
Strikingly, we also found synergy in gene activation by
combining the class I/II HDI, TSA, with increasing doses of
SPT to reactivate genes whose promoters have hypermethy-
lated DNA (Figure 2C and unpublished data). To again assess
the synergy with DNA demethylation, we used low titers of
shRNA retrovirus and low-dose Aza, and observed a
synergistic re-expression of SFRP1 and SFRP2 (Figure 2D).
The speciﬁc contribution of SIRT1 inhibition to the
synergistic effects of combining either Aza treatment or
TSA with sirtuin inhibition was investigated using low titers
of SIRT1H363Y retrovirus. We also observed the synergistic
reactivation of SFRP1 (Figure 2F, right panel), and GATA-5
and SFRP2 (unpublished data) in response to inhibition with
the SIRT1 dominant negative SIRT1H363Y (HY) when used
Figure 2. Pharmacologic and Dominant Negative Inhibition of SIRT1
Cause Re-Expression of TSGs and Synergize with 5-Deoxy-Azacytidine or
TSA
(A) Pharmacologic inhibition of SIRT1 causes TSG re-expression. MDA-
MB-231 cells were treated with 15 mM NIA or 300 lM SPT for 21 h, RNA
was isolated, and RT-PCR was performed with intron spanning primers
specific for the indicated genes. Control samples in which no reverse
transcriptase was added were analyzed separately, and all were negative
for amplification of the indicated genes.
(B) Combined treatment with low doses of Aza and SPT synergizes in the
re-expression of TSGs. MDA-MB-231 cells were treated with either 50 nM
Aza (þ), 100 lM SPT (þ) or with both Aza and SPT (þþ), and 34 h later, RT-
PCR was performed for the indicated genes as described in (A).
(C) Combined treatment with SPT and TSA synergize in the re-expression
of genes. MDA-MB-231 cells were treated with either 0, 50, 100, or 120
lM SPT alone for 34 h, or the treatment was followed by treatment with
300 nM TSA for 3 h prior to RNA isolation and RT-PCR analysis.
(D) SIRT1 protein knockdown synergizes with low doses of Aza for gene
re-expression. MDA-MB-231 cells were infected with low titers of virus for
shRNA specific for SIRT1. Aza (100 nM) was added 24 h prior to RNA
isolation, and RT-PCR analysis was performed for the genes SFRP1, SFRP2,
and GAPDH as described in (A).
(E) Dominant negative inhibition of SIRT1 leads to TSG re-expression in
MCF7 cells. MCF7 cells were infected with virus encoding either pBabe
(vec) or the catalytically inactive SIRT1H363Y (HY) mutant, and RT-PCR
was performed as described in (A).
(F) Dominant negative inhibition of SIRT1 leads to TSG re-expression and
synergizes with TSA and Aza. As shown in the left panel, MDA-MB-231
cells were infected with a control (vec) or mutant SIRT1 virus (HY), and
RT-PCR was performed as described in (A). MDA-MB-231 cells were
infected with low titers of pBabe or pBabe-SIRT1H363Y retrovirus and
subsequently treated with 100 nM Aza for 24 h or with 300 nM TSA for 3
h prior to harvest, and RT-PCR was performed.
DOI: 10.1371/journal.pgen.0020040.g002
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results provide strong evidence that, although SIRT1 inhib-
ition alone is sufﬁcient for the reactivation of our panel of
TSGs, inhibition of DNA methylation and class I/II HDACs
can cooperate with SIRT1 inhibition in such reactivation.
Given that SIRT1 appears to be intimately involved in
maintaining silencing of the genes under study whose
promoter DNA is densely hypermethylated, we wanted to
determine whether the mechanism of reactivation coincided
with any changes in the DNA methylation status at the re-
expressed TSG promoters. To assess this, we performed
extensive bisulﬁte sequencing of samples in which TSGs were
reactivated by transient knockdown of SIRT1 by RNAi as
shown in Figure 1 and by stable knockdown of SIRT1.
Strikingly, we observed no change in promoter methylation
of SFRP1 or GATA-5 (Figures 3A, S1, and S2). Moreover, a
very sensitive, methylation-speciﬁc PCR (MSP) approach for
detection of methylation status [38] yielded identical results
(Figure 3B) to those from bisulﬁte sequencing. In all previous
studies of these genes, a similar degree of reactivation with
Aza is always accompanied by signiﬁcant promoter demethy-
lation as assessed by MSP analyses or bisulﬁte sequencing
[28,34]. Furthermore, when the cells with stable RNAi
knockdown were treated with NIA to further inhibit any
remaining SIRT1 protein, as shown in the RNAi-2/NIA and
RNAi-3/NIA lanes in Figure 3B, we observed no restoration to
the unmethylated state for genes examined, even though they
were re-expressed. Thus, it appears that SIRT1 inhibition
alone is sufﬁcient for the reactivation of tested TSGs even
when dense promoter DNA methylation is maintained.
One question that emerges with the above re-expression of
genes induced by SIRT1 reduction in the face of retained
DNA methylation is how the extent of transcription achieved
compares to expression of these genes when DNA methyl-
ation alone is markedly reduced or absent. To examine this,
we compared by RT-PCR (Figure 4A) and by quantitative
real-time RT-PCR (Figure 4B) the re-expression achieved by
SIRT1 knockdown of two genes with the basal expression of
these same genes in an another cancer cell line in which the
promoter DNA is not hypermethylated (Figure 4). In RKO
cells in which SIRT1 protein levels were reduced via shRNA,
and the residual SIRT1 protein was inhibited with SPT, we
observed a restoration of CRBP1 and E-cadherin mRNA
transcripts to about 60%–75% of the levels for their basal
expression in HCT116 cells in which the promoter DNA is
not hypermethylated. Similarly, levels of re-expression of the
genes after SIRT1 reduction were comparable to those
achieved after decreased DNA methylation using intermedi-
ate doses of Aza (500 nM) (Figure 4). These results provide
evidence that SIRT1 inhibition plays a signiﬁcant role in TSG
re-expression even when promoter DNA methylation is
retained and that SIRT1 likely cooperates with factors other
than DNA methylation to help mediate the gene silencing.
How does SIRT1 function in contributing to the silencing of
DNA hypermethylated TSGs? To address this question, we
examined whether SIRT1 localizes to the promoters of the
hypermethylated genes studied and directly modulates his-
tonechanges. We performed chromatin immunoprecipitation
(ChIP) assays in MDA-MB-231 cells and observed SIRT1
localization at DNA-hypermethylated and silenced promoters
for SFRP1, E-cadherin, and GATA-5 (Figure 5 and unpublished
data) and at the silenced MLH1 and E-cadherin promoters in
RKO colon cancer cells (Figure 5C). This localization was
reduced with shRNA knockdown of SIRT1 (Figure 5A).
Importantly, SIRT1 was absent from the promoters of the
genes such as MLH1 and E-cadherin when their promoter DNA
is not hypermethylated and the genes are basally expressed in
the SW480 colon cancer cells (Figure 5C).
We next determined how modiﬁcations of lysine residues
known to be associated with transcriptional repression
mapped with SIRT1-associated gene silencing. During SFRP1
reactivation, and concurrent with shRNA knockdown of
SIRT1, we observed robust increases in acetylation of H4-K16
(Figure 5A and 5B) which has been documented as a direct
target of SIR2 in yeast [39–41] and a preferential target in
Figure 3. SIRT1 Inhibition Causes TSG Re-Expression without Changing
Promoter DNA Hypermethylation
(A) TSG re-expression occurs without changes in the methylation profile
of multiple clones analyzed for SFRP1 promoter methylation. Parallel
samples analyzed in Figure 1D were subjected to bisulfite sequencing of
the SFRP1 promoter from MDA-MB-231 cells stably infected with control
vector or RNAi-2 or RNAi-3 retrovirus. Open circles indicate unmethylated
cytosines, and closed circles indicate methylated cytosines. Numbers at
the bottom show the position of cytosines relative to the transcription
start site, which is at position 0, and those with a minus sign ( ) are
upstream from this start site. The region sequenced encompasses the
CpG island in which methylation status correlates with gene expression
status.
(B) MSP analyses of DNA from MDA-MB-231 cells stably expressing vector
control, RNAi-2, or RNAi-3 retrovirus. From left to right: (-) PCR Ctrl
indicates H2O only; (-) BS ctrl indicates bisulfite-treated H20; (þ) M ctrl
indicates the cell line in which SFRP1 is partially methylated and SFRP2
and GATA4 are fully methylated; and (þ) U ctrl indicates the Tera-2 cell
line in which each gene is unmethylated. All remaining lanes are for
MDA-MB-231. From left to right: Aza indicates 1 lM Aza (24 h) treatment;
Ctrl indicates empty vector infection; RNAi-2 indicates shRNA-2 infection
alone; RNAi-3 indicates shRNA-3 infection alone; Aza indicates 1 lM Aza
(24 h) treatment of control cells; Ctrl indicates empty vector infection þ
vehicle; RNAi-2 indicates shRNA-2 infection þ 5 mM NIA treatment; and
RNAi-3 indicates shRNA-3 infection þ 5 mM NIA treatment.
DOI: 10.1371/journal.pgen.0020040.g003
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system [11]. Additionally, we observed signiﬁcant increases in
the levels of H4-K16 acetylation at the SFRP1, E-cadherin, and
GATA-5 promoters (Figure 5A and 5B, and unpublished data).
We observed modest increases in H3-K9 acetylation at the
SFRP1 promoter and more substantial increases in H3-K9
acetylation at the E-cadherin promoter (Figure 4B). This latter
modiﬁcation has been tied to control by both class I and II
HDACs, and SIRT1 [7,42].
Finally, from an overall cellular phenotype, we might
predict that, if SIRT1 is involved in the repression of TSGs,
inhibiting its function and concomitant re-expression of such
genes should affect cell growth and/or viability. The numbers
of DNA-hypermethylated and silenced TSGs in the cancer
cell lines under examination make a direct analysis of this
difﬁcult. However, we tested the effects of SIRT1 on a series
of colon and breast cancer phenotypic characteristics that
would be predicted to change dramatically with re-expression
of the TSGs under study. First, we examined the numbers of
drug-resistant colonies that are formed during drug selection
of cells for stable siRNA (small interfering RNA) knockdown
of SIRT1. As shown in Figure 6A, we observed a sharp
reduction in cell colonies during such selection.
Although the re-expression of many genes could account
for the type of phenotypic change shown above, we queried
whether reactivation of SFRP genes might be involved. We
have shown previously that the silencing of the SFRP1 and -2
genes is important for aberrant activation of the Wnt
pathway in colon cancer cells, and their re-introduction into
such cells in which the genes are silenced causes sharp down-
regulation of Wnt pathway function and apoptosis. [28]. First,
we tested for the possible impact of the re-expression of these
genes in colon cancer cells by examining key parameters of
the Wnt signaling pathway following SIRT1 inhibition. We
found a 50% reduction in the activation of a b-catenin–
responsive TCF reporter construct, a canonical readout for
Wnt pathway activity in colon cancer cells [28,43,44] with SPT
treatment of RKO colon cancer cells (Figure 5B). Addition-
ally, we found a 50% reduction in the activation of a b-
Figure 4. SIRT1 Inhibition Causes Re-Expression of Epigenetically
Silenced TSGs
(A) RKO cells were infected and stably selected to express short hairpin
loop RNA targeting either a region unique to SIRT1 mRNA or a control
(ctrl). To inhibit any residual SIRT1 protein, remaining RNAi-expressing
cells were treated with 700 lM SPT and control samples were treated
with DMSO for 24 h. For comparison, control RNA was isolated from
parallel samples from HCT116 cells in which the two genes under study,
CRB1 and E-cadherin, do not have promoter DNA hypermethylation and
are basally expressed. RKO cells were also treated with 0.5 lM Aza (24 h),
and samples were analyzed as described in Figure 1A; RT-PCR was
performed with intron-spanning primers specific for the two genes.
GAPDH was also analyzed as a control. Only the shRNA (RNAi-3) that
caused substantial reduction in SIRT1 protein leads to gene re-
expression. Control samples in which no reverse transcriptase was
added were analyzed separately, and all were negative for amplification
of the indicated genes.
(B) Parallel samples described above were analyzed using real-time
quantitative PCR. The level of TSG re-expression induced by Aza
treatment or SIRT1 inhibition as described in (A) was compared to levels
of expression in HCT116 cells in which the TSGs are basally expressed.
DOI: 10.1371/journal.pgen.0020040.g004
Figure 5. SIRT1 Inhibition Causes Increases in Histone H4-K16
Acetylation at the Promoter of Re-Expressed Genes
(A) Pooled populations of MDA-MB-231 cells stably selected to express
RNAi constructs were analyzed via ChIP. These samples were isolated in
parallel to those analyzed in Figure 3B. ChIP was performed with
antibodies against SIRT1, acetylated histone H4, lysine 16 (H4-K16), or
with no antibody (NAB) controls. Each promoter sequence was amplified
by PCR under linear conditions for the genes SFRP1 and E-cadherin.
(B) The average change in SIRT1 localization, acetylation of H4-K16, and
acetylation of H3K9 at the SFRP1 and E-cadherin promoters as measured
by ChIP was quantitated for multiple experiments. Error bars indicate the
standard deviation for multiple experiments.
(C) SIRT1 localizes to the promoters of silent genes whose DNA is
hypermethylated, but not to these same promoters in cells in which the
genes are expressed. ChIP was performed with antibodies against SIRT1
in RKO and SW480 colon cancer cells. As shown in the left panel, SIRT1
localizes to the MLH1 promoter in RKO cells in which the gene is silent,
but not to the MLH1 promoter in SW480 cells in which it is expressed. As
shown in the right panel, SIRT1 localizes to the E-cadherin promoter in
RKO cells in which the gene is silent, but not to the E-cadherin promoter
in SW480 cells where it is expressed.
DOI: 10.1371/journal.pgen.0020040.g005
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[45,46] with SPT treatment of RKO cells (data not shown).
We also observed suppression of other Wnt pathway signaling
parameters in that there was a decrease in inactive phospho-
GSK-3b, a member of the b-catenin destruction complex, and
a reduction in cyclin D1 levels, a downstream target of
nuclear b-catenin (Figure 6). We further observed that
inhibition of SIRT1 lead to increases in p27 protein levels
in RKO cells, an observation consistent with another report
[47] using dominant negative inhibition of SIRT1 in another
cell type. As demonstrated in Figures 1 and 2 in breast cancer
cells, SIRT1 is involved in the silencing of SFRP1 and  2.
Moreover, MDA-MB-231 cells express the wnt7b oncogene
[48]. In MDA-MB-231 cells in which SIRT1 was inhibited
stably by RNAi, we observed a sharp reduction in the levels of
unphosphorylated or active b-catenin (Figure 5B). Thus,
SIRT1 inhibition causes re-expression of SFRPs that antag-
onize WNT signaling. Furthermore, SIRT1 inhibition causes
re-expression of the E-cadherin gene, whose protein product
complexes with b-catenin, and this gene reactivation collec-
tively may suppress the constitutive activation of the WNT
signaling pathway.
Discussion
Our ﬁndings for a prominent role for SIRT1 in epigenetic
silencing of genes whose promoters are hypermethylated in
cancer cells has important ramiﬁcations for the biology of
cancer. Multiple actions now attributed to SIRT1 indicate
that this protein could have important oncogenic roles. The
effects of knocking down SIRT1 levels on cancer cell
phenotypic features as found in our present study attest to
this. The mechanisms by which SIRT1 could serve as an
oncogene are multifactorial. First, there are data suggesting
high expression of this protein in a number of cancer cell
lines [49,50], and we have observed this as well (unpublished
data and [51]). Second, SIRT1 deacetylates several tran-
scription factors that could potentially compromise TSG
function, such as for p53 [21–23]. Third, single-copy increases
in SIRT1 orthologs in multiple organisms or application of
sirtuin activators have been shown to prolong cellular
lifespan [7,52]. Although this may obviously have beneﬁcial
effects in multiple cell settings, such prolongation may have a
damaging effect from the standpoint of selecting for neo-
plastic cells during tumor progression.
We now provide another mechanism through which SIRT1
might prolong survival of cells at risk for transformation by
participating in abnormal epigenetic silencing of TSGs. One
possible scenario that ties this role of SIRT1 to a cascade of
epigenetic events observed in cancer comes from our recent
observation that HIC1, a gene that is frequently epigenetically
silenced early in tumorigenesis, can be localized to the SIRT1
promoter. Thus, in Hic1-null MEFs (mouse embryonic
ﬁbroblasts), there is a corresponding increase in SIRT1 levels
[51]. Our current results indicate that the role of increased
levels of SIRT1 in the silencing of additional TSGs could also
contribute to its oncogenic potential and suggests a series of
epigenetic feedback events that would all predispose cells to
aberrant gene silencing. We tested the effects of SIRT1 on a
series of colon and breast cancer phenotypic characteristics
that would be predicted to change dramatically with re-
expression of the TSGs under study. We observed a reduction
in the numbers of drug-resistant colonies that are formed
during drug selection of cells for stable siRNA knockdown of
SIRT1. Although we observed a sharp reduction in cell
colonies during such selection, we acknowledge that there is
no way to know to what degree this effect is solely mediated
by the role of SIRT1 in the gene silencing studied in our
current work and/or how this would co-operate with other
SIRT1-mediated events. However, this result is consistent
with another report demonstrating that SIRT1 reduction via
RNAi induces either growth arrest or apoptosis in human
epithelial cancer cells and suggests an oncogenic role for
increased levels of this protein in cancer cells [53].
Another important possibility from our ﬁndings also
relates to the role of SIRT1 in lifespan prolongation and
delay of aging effects. The process of aging has been tightly
linked to increasing promoter DNA hypermethylation in
cancer-prone sites such as the human colon [54]. Certainly it
will now be important to study further whether this aging
response may involve related increases in SIRT1 levels that
may, in turn, facilitate aberrant gene silencing. From our
Figure 6. SIRT1 Inhibition Affects Key Phenotypic Aspects of Cancer Cells
(A) MDA-MB-231 cells were infected for two rounds with RNAi-2 and  3
retrovirus, and puromycin-resistant colonies were counted after 3 d of
selection. Error bars indicate standard deviation from the average of
three experiments.
(B) RKO cells were transfected with 500 ng of pGL3-OT, a TCF-
LEF responsive reporter, or pGL3-OF, a negative control with a mutated
TCF-LEF binding site in combination with 10 ng of pRL-CMV vector.
Twenty-four hours post-transfection, cells were treated with either
vehicle (DMSO) control or with 700 lM SPT for 24 h. Firefly luciferase
activity was measured and normalized to the Renilla luciferase activities.
(C) As described in (A), pooled populations of MDA-MB-231 cells stably
expressing RNAi-2 or RNAi-3 were harvested, protein concentrations
were determined, and Western blot analysis was performed. An antibody
that specifically recognizes the unphosphorylated (active) form of b-
catenin was used, and on the same blot, b-actin was probed to ensure
equal loading.
(D) Western blot analysis was performed on RKO cells expressing control
or SIRT1 RNAi. Antibodies against SIRT1, phospho-GSK3b (inactive), cyclin
D1, p27, and b-actin were used for Western blotting. On the same blot, b-
actin was probed to ensure equal loading.
DOI: 10.1371/journal.pgen.0020040.g006
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ing aberrant silencing of TSGs, but the question still remains
whether its increased expression is sufﬁcient for the initiation
of TSG silencing.
The mechanism through which SIRT1 participates in the
gene silencing accompanying DNA hypermethylation of TSGs
is also important to understand. Our present data indicate
that the protein plays its role by localizing to the promoters
of such silenced genes and deacetylating key histone lysine
residues that are known to be critical for transcriptional
repression. The targeting events for this recruitment will
additionally be important to understand. Interestingly, the
recent report that cancer cells have increased overall levels of
deacetylation of the known histone target of SIRT1, H4-K16
[55], could well be related to the ﬁndings we now report at
localized regions of aberrantly silenced TSGs. The role of
SIRT1 at other silenced genes, including those in normal cells
is not known. Considering the observations described here,
an important focus of future work should involve testing
whether SIRT1 associates with those few DNA-methylated
genes in normal settings that contain promoter CpG islands,
such as those on the inactive X chromosome of females or
silenced alleles of imprinted genes.
Finally, our ﬁndings have potential clinical relevance.
Combination therapies involving DNA-demethylating agents
and class I/II HDAC inhibitors are receiving much attention
for their potential therapeutic use in restoring expression of
abnormally silenced genes in cancer [15,16]. Targeting SIRT1
in these strategies may be especially important. We have
shown that blocking SIRT1 function synergizes with both
promoter demethylation and inhibition of class I and II
HDACs for gene reactivation and associated chromatin
modiﬁcation changes. Moreover, this inhibition of SIRT1
leads to gene reactivation even with retention of DNA
methylation. Our ﬁndings then suggest new directions for
targeting reversal of abnormal gene silencing and demon-
strate the importance of continued study, which may lead to
the eventual translation into the clinic.
Materials and Methods
Cell culture and retroviral infection. MDA-MB-231, MCF7,
HCT116, SW480 RKO, and Phoenix cells (ATCC, Rockville, Maryland,
United States) were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin (Invitrogen, Carlsbad, California, United States). Retro-
viral infection was performed using either single or multiple rounds
of infection. Brieﬂy, Phoenix cells were transfected with either pBabe,
pBabe-SIRT1H363Y, pSUPERretro, pSUPERretro-SIRT1-RNAi-1–3
(NM_012238 positions 410, 589, and 1091; Oligo Engine, Seattle,
Washington, United States) using Lipofectamine 2000 (Invitrogen).
After 48 h of transfection, the medium containing retrovirus was
collected, ﬁltered, and supplemented with Polybrene prior to
infection of target cells (MDA-MB-231, MCF7, or HCT116). Infected
cells were either harvested 24–48 h later or subjected to selection with
2–3 lg/ml puromycin for a week prior to harvest and analysis.
RNA and protein preparation and analysis. Total RNA was
extracted (Invitrogen) according to the manufacturer’s instructions
and subjected to reverse transcription followed by both quantitative
real-time and semi-quantitative polymerase chain reaction. For
quantitative real-time analyses, the QuantiTect SYBR Green PCR
kit (Qiagen, Valencia, California, United States) was used and the
ampliﬁcation conditions consisted of an initial 10-min denaturation
step at 95 8C, followed by 40 cycles of denaturation at 95 8C for 15 s
and annealing and extension for 30 s and 60 s, respectively. A BioRad
iCycler was used (BioRad, Hercules, California, United States), and
for quantitation the comparative cycle threshold (Ct) method was
used, normalizing the Ct values for the indicated gene to the Ct values
of GAPDH relative to a control sample. For conventional PCR, at
least two independent sets of intron-spanning primers [28,34,56]
were used for the analysis of multiple genes, such as CRBP1,
(NM_002899), E-cadherin, (L34545), SFRP1, (BC036503), SFRP2,
(BC008666), and Gata-4 (L34357). For Western blots, cells stably
expressing RNAi constructs were harvested in 50 mM Tris-HCl, 1%
NP-40, .25% sodium deoxycholate, 150 mM NaCl, 50 mM sodium
ﬂuoride, 1 mM dithiothreitol, 1 mM AEBSF, 13 Complete protease
inhibitor cocktail (Roche, Basel, Switzerland). Protein concentrations
were measured by BCA (Pierce Biotechnology, Rockford, Illinois,
United States). Protein extracts were subjected to polyacrylamide gel
electrophoresis using the 4%–12% NuPAGE gel system (Invitrogen),
transferred to PVDF (Millipore, Billerica, Massachusetts, United
States) membranes, and immunoblotted using antibodies that
speciﬁcally recognize SIRT1 (DB083; Delta Biolabs, Gilroy, California,
United States, and 05–707; Upstate, Charlottesville, Virginia, United
States), E-cadherin (Transduction Laboratories 610182; BD Bioscien-
ces, San Diego, California, United States), hMLH1 (551091; BD
Biosciences), cyclin D1 (556470; BD Biosciences), p27
Kip1 (Trans-
duction Laboratories K25020; BD Biosciences), the unphosphorylated
(active) form of b-catenin (05–665; Upstate), and phospho-GSK3b
(05–643; Upstate). On the same blot, b-actin (Sigma, St. Louis,
Missouri, United States) was probed to ensure equal loading.
Reporter assays were performed as described previously using the
b-catenin–responsive TCF reporter [28] and the cyclin D1 reporter.
Brieﬂy, prior to transfection, RKO cells were plated in six-well tissue
culture dishes and grown until they reached 80%–90% conﬂuence.
Cells were transfected with 500 ng of pGL3-OT, a TCF-
LEF responsive reporter, or pGL3-OF, a negative control with a
mutated TCF-LEF binding site in combination with 10 ng of pRL-
CMV vector. Twenty-four hours post-transfection, cells were treated
with either vehicle (DMSO) control or with 700 lM SPT for 24 h.
According to the manufacturer’s instructions, Fireﬂy luciferase activity
was measured via a luminometer (BD Biosciences) and normalized to
the Renilla luciferase activities by using the Dual Luciferase Reporter
System (Promega, Madison, Wisconsin, United States).
ChIP. ChIP analysis was performed as previously described [4] with
a few modiﬁcations. Antibodies to SIRT1 (05–707 and 07–313), acetyl-
sH3-K9 (07–352), and acetyl-H4-K16 (07–329) were obtained from
Upstate. Antibodies to SIRT1 were also obtained from Delta Biolabs
(DB083). Primers (Forward: AGCCGCGTCTGGTTCTAGT; Reverse:
GGAGGCTGCAGGGCTG) were designed for the SFRP1 promoter
spanning  163 to þ12 relative to the transcription start site (þ1) and
were ampliﬁed by PCR under linear conditions. Enrichment was
calculated as the ratio between the net intensity of the bound SFRP1
sample divided by the input and the vector control sample divided by
the input. Primers for E-cadherin were (Forward: TAGAGGGT
CACCGCGTCTATG) and (Reverse: GGGTGCGTGGCTGCAGC
CAGG), which encompass a CAAT signal.
MSP and bisulﬁte sequencing. MSP and bisulﬁte sequencing were
performed as previously described [28,38] on DNA from MDA-MB-
231 cells both transiently and stably infected with control vector or
RNAi retrovirus.
Supporting Information
Figure S1. SIRT1 Inhibition Causes TSG Re-Expression without
Changing SFRP1 Promoter DNA Hypermethylation
Bisulﬁte sequencing was performed on the SFRP1 promoter from
MDA-MB-231 cells stably infected with control vector or RNAi-3
retrovirus as described in Figure 3. Open circles indicate unmethy-
lated cytosines and closed circles indicate methylated cytosines.
Numbers at the bottom show position of cytosines relative to the
transcription start site, which is at position 0, and those with a minus
sign ( ) are upstream from this start site. The region sequenced
encompasses the CpG island in which methylation status correlates
with gene expression status.
Found at DOI: 10.1371/journal.pgen.0020040.sg001 (2.0 MB EPS).
Figure S2. SIRT1 Inhibition Causes TSG Re-Expression without
Changing GATA-5 Promoter DNA Hypermethylation
Bisulﬁte sequencing was performed on the GATA-5 promoter from
MDA-MB-231 cells stably infected with control vector or RNAi-3
retrovirus as described in Figure 3. The region sequenced has
previously been shown to be the region in which methylation occurs
that most closely correlates with transcriptional activity. Open circles
indicate unmethylated cytosines, and closed circles indicate methy-
lated cytosines. Numbers at the bottom show position of cytosines
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SIRT1 Regulates Cancer Gene Silencingrelative to the transcription start site, which is at position 0, and those
with a minus sign ( ) are upstream from this start site. The region
sequenced encompasses the CpG island in which methylation status
correlates with gene expression status.
Found at DOI: 10.1371/journal.pgen.0020040.sg002 (1.5 MB EPS).
Accession Numbers
The National Center for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov) accession numbers for the genes and gene
products discussed in this paper are CRBP1 (GeneID: 5947), cyclin-D1
(GeneID: 595), E-cadherin (GeneID: 999), GATA-5 (GeneID: 140628),
MLH1 (GeneID: 4292), SFRP1 (GeneID: 6422), and SFRP2 (GeneID:
6423). The accession numbers for the proteins discussed in this paper
are b-catenin (P35222), cyclin D1 (P24385), phospho-GSK-3b
(P49841), and Sir2 (P53685).
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